1h Free Analyst Time
Global Post-Traumatic Stress Disorder (PSTD) Therapeutics Market 2020-2024Speak directly to the analyst to clarify any post sales queries you may have.
The author has been monitoring the global post-traumatic stress disorder (PSTD) therapeutics market and it is poised to grow by USD 909.86 mn during 2020-2024, progressing at a CAGR of 9% during the forecast period. Our reports on post-traumatic stress disorder (PSTD) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of PSTD. In addition, increasing initiatives by public and private organizations is anticipated to boost the growth of the post-traumatic stress disorder (PSTD) therapeutics market as well.
Market Segmentation
The global post-traumatic stress disorder (PSTD) therapeutics market is segmented as below:
Product
- Antidepressants
- Anxiolytics
- Other PSTD therapeutics
Geographic segmentation
- APAC
- Europe
- MEA
- North America
- South America
Key Trends for post-traumatic stress disorder (PSTD) therapeutics market growth
This study identifies increasing initiatives by public and private organizations as the prime reasons driving the post-traumatic stress disorder (PSTD) therapeutics market growth during the next few years.
Prominent vendors in post-traumatic stress disorder (PSTD) therapeutics market
We provide a detailed analysis of around 25 vendors operating in the post-traumatic stress disorder (PSTD) therapeutics market, including some of the vendors such as AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG and Pfizer Inc. .
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Table of Contents
- Executive Summary
- Market Overview
- Market Landscape
- Market ecosystem
- Value chain analysis
- Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
- Five Forces Analysis
- Five Forces Summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market Segmentation by Product
- Market segments
- Comparison by Product placement
- Antidepressants - Market size and forecast 2019-2024
- Anxiolytics - Market size and forecast 2019-2024
- Other PTSD therapeutics - Market size and forecast 2019-2024
- Market opportunity by Product
- Customer landscape
- Overview
- Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- APAC - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- South America - Market size and forecast 2019-2024
- MEA - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Drivers, Challenges, and Trends
- Market drivers
- Volume driver - Demand led growth
- Volume driver - Supply led growth
- Volume driver - External factors
- Volume driver - Demand shift in adjacent markets
- Price driver - Inflation
- Price driver - Shift from lower to higher priced units
- Market challenges
- Market trends
- Vendor Landscape
- Overview
- Vendor landscape
- Landscape disruption
- Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc
- Azevan Pharmaceuticals Inc.
- Bionomics Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- H. Lundbeck AS
- Mylan NV
- Neurocrine Biosciences Inc.
- Novartis International AG
- Pfizer Inc.
- Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 4
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Market in focus
- Parent market
- Market characteristics
- Product/Service portfolio of key vendors included in the market definition
- Market segments
- Global - Market size and forecast 2019 - 2024 ($ million)
- Global market: Year-over-year growth 2019 - 2024 (%)
- Five forces analysis 2019 & 2024
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2019
- Product placement - Market share 2019-2024 (%)
- Comparison by Product placement
- Antidepressants - Market size and forecast 2019-2024 ($ million)
- Antidepressants - Year-over-year growth 2019-2024 (%)
- Anxiolytics - Market size and forecast 2019-2024 ($ million)
- Anxiolytics - Year-over-year growth 2019-2024 (%)
- Other PTSD therapeutics - Market size and forecast 2019-2024 ($ million)
- Other PTSD therapeutics - Year-over-year growth 2019-2024 (%)
- Market opportunity by Product
- Customer landscape
- Market share by geography 2019-2024 (%)
- Geographic comparison
- North America - Market size and forecast 2019-2024 ($ million)
- North America - Year-over-year growth 2019-2024 (%)
- APAC - Market size and forecast 2019-2024 ($ million)
- APAC - Year-over-year growth 2019-2024 (%)
- Europe - Market size and forecast 2019-2024 ($ million)
- Europe - Year-over-year growth 2019-2024 (%)
- South America - Market size and forecast 2019-2024 ($ million)
- South America - Year-over-year growth 2019-2024 (%)
- MEA - Market size and forecast 2019-2024 ($ million)
- MEA - Year-over-year growth 2019-2024 (%)
- Key leading countries
- Market opportunity by geography ($ million)
- Impact of drivers
- Impact of challenges
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc - Overview (1/3)
- AstraZeneca Plc - Overview (2/3)
- AstraZeneca Plc - Overview (3/3)
- AstraZeneca Plc - Product and service
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Key customers
- AstraZeneca Plc - Segment focus
- Azevan Pharmaceuticals Inc. - Overview (1/3)
- Azevan Pharmaceuticals Inc. - Overview (2/3)
- Azevan Pharmaceuticals Inc. - Overview (3/3)
- Azevan Pharmaceuticals Inc. - Product and service
- Azevan Pharmaceuticals Inc. - Key offerings
- Azevan Pharmaceuticals Inc. - Key customers
- Azevan Pharmaceuticals Inc. - Segment focus
- Bionomics Ltd. - Overview (1/3)
- Bionomics Ltd. - Overview (2/3)
- Bionomics Ltd. - Overview (3/3)
- Bionomics Ltd. - Business segments
- Bionomics Ltd. - Key offerings
- Bionomics Ltd. - Key customers
- Bionomics Ltd. - Segment focus
- Eli Lilly and Co. - Overview (1/3)
- Eli Lilly and Co. - Overview (2/3)
- Eli Lilly and Co. - Overview (3/3)
- Eli Lilly and Co. - Business segments
- Eli Lilly and Co. - Key offerings
- Eli Lilly and Co. - Key customers
- Eli Lilly and Co. - Segment focus
- GlaxoSmithKline Plc - Overview (1/3)
- GlaxoSmithKline Plc - Overview (2/3)
- GlaxoSmithKline Plc - Overview (3/3)
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Key customers
- GlaxoSmithKline Plc - Segment focus
- H. Lundbeck AS - Overview (1/3)
- H. Lundbeck AS - Overview (2/3)
- H. Lundbeck AS - Overview (3/3)
- H. Lundbeck AS - Product and service
- H. Lundbeck AS - Key offerings
- H. Lundbeck AS - Key customers
- H. Lundbeck AS - Segment focus
- Mylan NV - Overview (1/3)
- Mylan NV - Overview (2/3)
- Mylan NV - Overview (3/3)
- Mylan NV - Business segments
- Mylan NV - Key offerings
- Mylan NV - Key customers
- Mylan NV - Segment focus
- Neurocrine Biosciences Inc. - Overview (1/3)
- Neurocrine Biosciences Inc. - Overview (2/3)
- Neurocrine Biosciences Inc. - Overview (3/3)
- Neurocrine Biosciences Inc. - Business segments
- Neurocrine Biosciences Inc. - Key offerings
- Neurocrine Biosciences Inc. - Key customers
- Neurocrine Biosciences Inc. - Segment focus
- Novartis International AG - Overview (1/3)
- Novartis International AG - Overview (2/3)
- Novartis International AG - Overview (3/3)
- Novartis International AG - Business segments
- Novartis International AG - Key offerings
- Novartis International AG - Key customers
- Novartis International AG - Segment focus
- Pfizer Inc. - Overview (1/3)
- Pfizer Inc. - Overview (2/3)
- Pfizer Inc. - Overview (3/3)
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Key customers
- Pfizer Inc. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The following companies as the key players in the global post-traumatic stress disorder (PSTD) therapeutics market: AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG and Pfizer Inc.Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is increasing initiatives by public and private organizations”
According to the report, one of the major drivers for this market is the rising prevalence of PSTD.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- Azevan Pharmaceuticals Inc.
- Bionomics Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- H. Lundbeck AS
- Mylan NV
- Neurocrine Biosciences Inc.
- Novartis International AG
- Pfizer Inc.
